The Greater Cannabis Company, Inc. (GCAN) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-56027
Entity Registrant Name	THE GREATER CANNABIS COMPANY, INC.
Entity Central Index Key	0001695473
Entity Tax Identification Number	30-0842570
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	15 Walker Avenue Suite 101
Entity Address, City or Town	Baltimore
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21208
City Area Code	(443)
Local Phone Number	738-4051
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		508,638,436

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 456,358	$ 112,953
Note receivable	36,750	36,750
Prepaid officer compensation		10,000
Total current assets	493,108	159,703
OTHER ASSETS
Right of first refusal agreement cost (less accumulated amortization of $7,083 and $4,583)	16,667	20,417
Total assets	509,775	180,120
CURRENT LIABILITIES
Accounts payable	8,442	6,743
Accrued interest	12,308	849
Accrued officers’ compensation	203,000	152,000
Loans payable to related parties	260,000	260,000
Notes payable to third parties (less debt discounts of $168,681 and $0, respectively)	298,756	22,875
Derivative liability		17,441
Total current liabilities and total liabilities	782,506	459,908
STOCKHOLDERS’ (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value: Series A Convertible Preferred-issued and outstanding 9,111,998 and 9,411,998 shares, respectively	9,112	9,412
Common stock; 2,000,000,000 shares authorized, $.001 par value, as of September 30, 2021 and December 31, 2020, there are 508,638,436 and 464,843,318 shares outstanding, respectively	508,639	464,843
Additional paid-in capital	2,945,821	2,576,365
Accumulated deficit	(3,736,303)	(3,330,408)
Total stockholders’ (deficiency)	(272,731)	(279,788)
Total liabilities and stockholders’ (deficiency)	$ 509,775	$ 180,120

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Accumulated Amortization	$ 7,083	$ 4,583
Debt Instrument, Unamortized Discount, Current	$ 168,681	$ 0
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ 1	$ 1
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, par value	$ 1	$ 1
Common stock, shares outstanding	508,638,436	464,843,318
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,111,998	9,411,998
Preferred stock, shares outstanding	9,111,998	9,411,998

Consolidated Statement of Opera

Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue			$ 12,630	$ 48,044
Cost of product sales			12,655	48,090
Gross profit (loss)			(25)	(46)
Operating Expenses:
Officers compensation	19,000	51,000	121,000	153,000
Amortization of Right of First Refusal Agreement cost	1,250	1,250	3,750	3,333
Other operating expenses	54,088	18,675	98,269	84,546
Total operating expenses	74,338	70,925	223,019	240,879
Income (loss) from operations	(74,338)	(70,925)	(223,044)	(240,925)
Other income (expenses):
Income (expense) from derivative liability		213,751	407,370	909,596
Loss on conversions/issuances of notes payable	(52,716)	(467,555)	(379,434)	(829,342)
Gain from Surrender Agreement with Emet Capital Partners, LLC				472,170
Forgiveness of royalty payable		50,000		50,000
Interest expense	(7,478)	(6,251)	(12,272)	(59,726)
Amortization of debt discounts	(117,746)	(178,280)	(198,515)	(870,153)
Total other income (expenses)	(177,940)	(388,335)	(182,851)	(327,455)
Income (loss) before provision for income taxes	(252,278)	(459,260)	(405,895)	(568,380)
Provision for income taxes
Net income (loss)	$ (252,278)	$ (459,260)	$ (405,895)	$ (568,380)
Basic and diluted income (loss) per common share	$ 0	$ 0	$ 0	$ (0.01)
Weighted average common shares outstanding-basic and diluted	492,984,603	130,367,164	483,124,241	84,172,283
Product [Member]
Revenue:
Total revenue			$ 12,630	$ 48,044

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Balances at June 30, 2021	$ (86,452)	$ (348,917)	$ (279,788)	$ (1,039,129)	$ (2,352,110)	$ (1,546,634)	$ (279,788)	$ (1,546,634)
Conversion of FirstFire note	65,999	39,000
Valuation of warrants		262,429
Converted 300,000 shares of Series A Preferred Shares into 15,000,000 Shares of common stock
Conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,524) for the three months ended March 31, 2021			45,524	797,067	210,532	406,093
Net Income (loss)	(252,278)	(38,964)	(114,653)	(459,260)	1,102,449	(1,211,569)	(405,895)	(568,380)
Balances at September 30, 2021	(272,731)	(86,452)	(348,917)	(701,322)	(1,039,129)	(2,352,110)	(272,731)	(701,322)
Common Stock [Member]
Balances at June 30, 2021	$ 483,639	$ 478,639	$ 464,843	$ 88,350	$ 60,786	$ 39,301	$ 464,843	$ 39,301
Balance, shares	478,638,436	478,638,436	464,843,318	88,349,536	60,786,011	39,301,323	464,843,318	39,301,323
Conversion of FirstFire note	$ 10,000	$ 5,000
Conversion of FirstFire note	10,000,000
Converted 300,000 shares of Series A Preferred Shares into 15,000,000 Shares of common stock	$ 15,000
Converted shares of series preferred shares into shares of common stock shares	15,000,000
Conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,524) for the three months ended March 31, 2021			$ 13,796	$ 115,277	$ 27,564	$ 21,485
Conversion of note payable			13,795,118	115,277,834	27,563,525	21,484,688
Net Income (loss)
Balances at September 30, 2021	$ 508,639	$ 483,639	$ 478,639	$ 203,627	$ 88,350	$ 60,786	$ 508,639	$ 203,627
Balance, shares	508,638,436	478,638,436	478,638,436	203,627,370	88,349,536	60,786,011	508,638,436	203,627,370
Additional Paid-in Capital [Member]
Balances at June 30, 2021	$ 2,904,522	$ 2,608,093	$ 2,576,365	$ 1,351,467	$ 1,168,499	$ 783,891	$ 2,576,365	$ 783,891
Conversion of FirstFire note	55,999	34,000
Valuation of warrants		262,429
Converted 300,000 shares of Series A Preferred Shares into 15,000,000 Shares of common stock	(14,700)
Conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,524) for the three months ended March 31, 2021			31,728	681,790	182,968	384,608
Net Income (loss)
Balances at September 30, 2021	2,945,821	2,904,522	2,608,093	2,033,257	1,351,467	1,168,499	2,945,821	2,033,257
Retained Earnings [Member]
Balances at June 30, 2021	(3,484,025)	(3,445,061)	(3,330,408)	(2,488,358)	(3,590,807)	(2,379,238)	(3,330,408)	(2,379,238)
Net Income (loss)	(252,278)	(38,964)	(114,653)	(459,260)	1,102,449	(1,211,569)
Balances at September 30, 2021	(3,736,303)	(3,484,025)	(3,445,061)	(2,947,618)	(2,488,358)	(3,590,807)	(3,736,303)	(2,947,618)
Series A Preferred Stock [Member] | Preferred Stock [Member]
Balances at June 30, 2021	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412
Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998
Converted 300,000 shares of Series A Preferred Shares into 15,000,000 Shares of common stock	$ (300)
Converted shares of series preferred shares into shares of common stock shares	(300,000)
Conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,524) for the three months ended March 31, 2021
Net Income (loss)
Balances at September 30, 2021	$ 9,112	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,112	$ 9,412
Balance, shares	9,111,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,111,998	9,411,998

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Unaudited) (Parenthetical) - USD ($)	Sep. 21, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Notes Payable		$ 311,050	$ 67,082	$ 22,500				$ 165,350
Interest Payable		$ 18,462	$ 10,613	$ 814	$ 16,849	$ 18,462	$ 10,613	$ 11,793
Debt Conversion, Converted Instrument, Shares Issued		115,277,834	27,563,525	13,795,118	261,215,948	115,277,834	27,563,525	21,484,688
Debt Conversion, Converted Instrument, Amount		$ 797,067	$ 210,532	$ 45,524	$ 804,324	$ 797,067	$ 210,532	$ 406,093
Common Stock [Member]
Converted shares of common stock		15,000,000
Series A Preferred Stock [Member]
Converted shares of common stock	15,000,000	300,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
OPERATING ACTIVITIES
Net income (loss)	$ (405,895)	$ (568,380)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Loss on conversion of notes payable and accrued interest to common stock	379,434	829,342
Gain from Surrender Agreement with Emet Capital Partners, LLC		(472,170)
(Income) expense from derivative liability	(407,370)	(909,596)
Forgiveness of royalty payable		50,000
Amortization of Right of First Refusal Agreement cost	3,750	3,333
Amortization of debt discounts	198,515	870,153
Changes in operating assets and liabilities:
Prepaid officer compensation	10,000
Advance to supplier		28,000
Note receivable		(23,575)
Accounts payable	1,699	(10,554)
Accrued interest	12,272	32,726
Accrued salaries	51,000	38,000
Advance from customer		(27,977)
Net cash used in operating activities	(156,595)	(260,698)
INVESTING ACTIVITIES
Purchase of Right of First Refusal Agreement		(25,000)
Net cash used in investing activities		(25,000)
FINANCING ACTIVITIES
Amount paid in connection with Surrender Agreement with Emet Capital Partners, LLC		(72,000)
Proceeds from notes payable to third parties	500,000	506,668
Net cash provided by financing activities	500,000	439,668
NET INCREASE IN CASH	343,405	153,970
CASH BALANCE, BEGINNING OF PERIOD	112,953	24,662
CASH BALANCE, END OF PERIOD	456,358	178,632
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income tax paid
Non-cash Investing and Financing Activities:
Initial derivative liability charged to debt discounts	500,000	509,667
Issuances of warrants	296,428
Conversion of note payable ($22,500) and accrued interest ($814) into 13,795,118 shares of common stock (Fair Value of $45,524) for the Six months ended June 30, 2021	45,524
Conversions of notes payable ($165,350) and accrued interest ($11,793) into 21,484,688 shares of common stock (Fair Value of $406,093) for the three months ended March 31, 2020		406,093
Conversions of notes payable ($67,082) and accrued interest ($10,613) into 27,563,525 shares of common stock (Fair Value of $210,582) for the three months ended June 30, 2020		210,532
Conversions of notes payable ($311,050) and accrued interest ($18,462) into 115,277,834 shares of common stock (Fair Value of $797,067) for the three months ended September 30, 2020		$ 797,067

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	3 Months Ended			6 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021
Short-term Debt [Line Items]
Notes payable			$ 165,350	$ 67,082
Accrued interest	$ 18,462	$ 10,613	$ 11,793	10,613
Shares of common stock	115,277,834	27,563,525	21,484,688
Fair value of common stock	$ 797,067	$ 210,532	$ 406,093
Notes Payable [Member]
Short-term Debt [Line Items]
Notes payable	311,050	67,082	165,350	22,500
Accrued interest	$ 18,462	$ 10,613	$ 11,793	$ 814
Shares of common stock	115,277,834	27,563,525	21,484,688	13,795,118
Fair value of common stock	$ 797,067	$ 210,582	$ 406,093	$ 45,524

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 94 Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx Inc. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Interim Financial Statements The interim financial statements as of September 30, 2021 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the nine and three months ended September 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2020 as included in our report on Form 10-K. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2021, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured using level three inputs on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. (see Note-G) Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Equity Instruments Issued to Non-Employees for Acquiring Goods or Services The Company in the current period has updated for ASU 2018-07 as it was effective in 2019. The Company is evaluating the impact of the new ASU; however, it is not expected to have a material impact on the financial statements. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: ● Identify the contract(s) with a customer ● Identify the performance obligations ● Determine the transaction price ● Allocate the transaction price ● Recognize revenue when the performance obligations are met During the period ended September 30, 2021 and 2020, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customer, and as such, recognizes revenue at the time the customer takes possession. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 see NOTE F - NOTES PAYABLE TO THIRD PARTIES see NOTE H - CAPITAL STOCK AND WARRANTS Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presented. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance became effective for annual periods beginning after December 15, 2018.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of September 30, 2021, the Company had cash of $ 456,358 , total current liabilities of $ 782,506 and negative working capital of $ 289,398 . For the nine months ended September 30, 2021, we incurred a net loss of $ 405,895 and used $ 156,595 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through November 2022. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

NOTE RECEIVABLE

NOTE RECEIVABLE	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
NOTE RECEIVABLE	NOTE C – NOTE RECEIVABLE On June 10, 2020, in anticipation of developing a CBD business with Koltuv Ventures, LLC (the “Borrower”) (see Note D), the Company agreed to lend the Borrower USD $ 50,000 2 36,750

RIGHT OF FIRST REFUSAL AGREEMEN

RIGHT OF FIRST REFUSAL AGREEMENT	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
RIGHT OF FIRST REFUSAL AGREEMENT	NOTE D – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being (“KTV”). The Agreement provided for the Company to pay KTV $ 25,000 five years 25,000

LOANS PAYABLE TO RELATED PARTIE

LOANS PAYABLE TO RELATED PARTIES	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
LOANS PAYABLE TO RELATED PARTIES	NOTE E - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 80,000 80,000 Total $ 260,000 $ 260,000 Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $ 1,500,000 These loans were extended during the period for an additional 24 months.

NOTES PAYABLE TO THIRD PARTIES

NOTES PAYABLE TO THIRD PARTIES	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE TO THIRD PARTIES	NOTE F - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES September 30, 2021 December 31, 2020 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4 September 28, 2017 .001 $ 375 $ 375 (i) 6 February 12, 2020 - 22,500 (ii) 6 March 11, 2022 168,681 0 298,381 - Total $ 298,756 $ 22,875 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% 1,200,000 96,000 1,104,000 250,000 166,500 93,666 February 12, 2020 42,500 one 65% 15 0 (ii) On March 15, 2021, we issued a 6% 545,000 272,500 22,500 272,500 22,500 March 11, 2022 PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I) THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE F - NOTES PAYABLE TO THIRD PARTIES (continued) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four ( 24 70 125 THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

DERIVATIVE LIABILITY

DERIVATIVE LIABILITY	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITY	NOTE G - DERIVATIVE LIABILITY The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY September 30, 2021 December 31, 2020 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ $ 17,441 Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note F (ii) - - Total derivative liability $ - $ 17,441 THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE G - DERIVATIVE LIABILITY (continued) The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. As of June 30, 2021, the note no longer carries variable conversion features and as such, the derivative was reduced to zero. The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $ .003 per share, (2) conversion price of $ .00169 per share, (3) term of 0 142.94 %, and (5) risk free interest rate of 0 %.

CAPITAL STOCK AND WARRANTS

CAPITAL STOCK AND WARRANTS	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
CAPITAL STOCK AND WARRANTS	NOTE H - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 On February 14, 2019, the Company issued 9,000,000 Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $ 0.075 On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $ 20,399 5,189 25,587 6 February 12, 2020 75 15 9,000,000 675,000 2 October 18, 2020 75 15 On September 21, 2021, 300,000 15,000,000 Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 5,378,476 19.99 21,527,493 500 80.01 THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE H - CAPITAL STOCK AND WARRANTS (continued) During the three months ended March 31, 2020, the Company issued a total of 21,484,688 165,350 11,793 228,949 406,093 21,484,688 177,143 During the three months ended June 30, 2020, the Company issued a total of 27,563,525 67,082 10,613 132,838 210,532 27,563,525 77,695 During the three months ended September 30, 2020, the Company issued a total of 115,277,834 311,050 18,462 467,554 797,067 115,277,834 329,512 During the three months ended December 31, 2020, the Company issued a total of 261,215,948 325,212 16,849 462,263 804,324 261,215,948 342,061 During the three months ended June 30, 2021, the Company recorded the value of the warrants at $ 262,429 39,000 On July 15, 2021, the Company issued 10,000,000 shares for the conversion of $ 52,080 principal on the FirstFire note dated March 5, 2021 at a conversion price of $ .005208 . 52,716 THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE H - CAPITAL STOCK AND WARRANTS (continued) Warrants On March 11, 2021, in connection with the issuance of a Convertible Promissory Note to FirstFire Global Opportunities Fund, LLC (“FF”) (see Note F), we issued three warrants (Warrant A, Warrant B and Warrant C) to purchase shares of our common stock, as follows: Warrant A permits FF to purchase 25,000,000 0.025 Warrant B permits FF to purchase 15,000,000 0.05 Warrant C permits FF to purchase 10,000,000 0.075 Each warrant has other customary terms found in like instruments, including, but not limited to, events of default. In any event of default, the exercise price for each warrant automatically becomes $ 0.005 Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021 and the above summary of the warrant terms are subject to full terms of the applicable warrants.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE I - INCOME TAXES The Company and its United States subsidiaries file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, files Canada and Ontario income tax returns. At September 30, 2021 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company, it is not more likely than not that the benefits will be realized. If there are significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE J - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provided for Green C payments to Pharmedica of a $ 100,000 5 50,000 The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $ 50,000 69,749 69,749 0 On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $ 50,000 50,000 0 THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE J - COMMITMENTS AND CONTINGENCIES (continued) Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10 17 On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $ 1,000,000 To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Service Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”) and its then newly appointed Chief Legal Officer (the “CLO”), for terms of five years. The Agreements provide for a monthly base salary of $ 10,000 7,000 102,000 102,000 Registration Rights Agreement$ On March 11, 2021, we entered into a registration rights agreement pursuant to which we agreed to prepare and file with the SEC a registration statement or registration statements (as is necessary) covering the resale- of all of the shares of common stock into which the FF Note is convertible and the shares to be received upon the exercise of the warrants. The registration statement also covers such indeterminate number of additional shares of securities as may become issuable upon stock splits, stock dividends or similar transactions. The registration statement on Form S-1 was declared effective by the SEC on June 28, 2021. A copy of the registration rights agreement is attached as Exhibit 10.2 to our current report on Form 8-K dated March 16, 2021 and the above summary of the registration rights agreement terms is subject to full terms of the registration rights agreement. Licensing Agreement and Research Agreement with Shaare Zedek Scientific Ltd. On August 19, 2021, GCAN issued a press release announcing that it had entered into a Licensing Agreement and a Research Agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center. The agreements cover the licensing of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders, as well as additional clinical research to be conducted with respect to the therapeutic. Payments timeline are as follows: August 1, 2021 $ 35,000 35,000 23,000 70,000 77,482 27,000 The foregoing item was set forth in a Current Report on Form 8-K filed by the Company with the SEC on August 19, 2021. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE K- SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were available to be issued. The Company had no subsequent events that required disclosure.

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100 9,411,998 Each share of Series A Convertible Preferred Stock is convertible into 50 94 Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx Inc.
Interim Financial Statements	Interim Financial Statements The interim financial statements as of September 30, 2021 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the nine and three months ended September 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2020 as included in our report on Form 10-K.
Cash and Cash Equivalents	Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents.
Income Taxes	Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2021, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments and Fair Value of Financial Instruments	Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured using level three inputs on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. (see Note-G)
Derivative Liabilities	Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Long-lived Assets	Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services The Company in the current period has updated for ASU 2018-07 as it was effective in 2019. The Company is evaluating the impact of the new ASU; however, it is not expected to have a material impact on the financial statements.
Related Parties	Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) Revenue recognition: The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on January 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, in accordance with the following five-step process: ● Identify the contract(s) with a customer ● Identify the performance obligations ● Determine the transaction price ● Allocate the transaction price ● Recognize revenue when the performance obligations are met During the period ended September 30, 2021 and 2020, all revenue was from sales of cannabis products. The Company has determined the sole performance obligation to be the delivery of the purchased goods to the customer, and as such, recognizes revenue at the time the customer takes possession.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no
Loss per Share	Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 see NOTE F - NOTES PAYABLE TO THIRD PARTIES see NOTE H - CAPITAL STOCK AND WARRANTS
Recently Enacted Accounting Standards	Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presented. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance became effective for annual periods beginning after December 15, 2018.

LOANS PAYABLE TO RELATED PART_2

LOANS PAYABLE TO RELATED PARTIES (Tables)	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES	Loans payable to related parties consist of: SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 80,000 80,000 Total $ 260,000 $ 260,000

NOTES PAYABLE TO THIRD PARTIES

NOTES PAYABLE TO THIRD PARTIES (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES	Notes payable to third parties consist of: SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES September 30, 2021 December 31, 2020 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4 September 28, 2017 .001 $ 375 $ 375 (i) 6 February 12, 2020 - 22,500 (ii) 6 March 11, 2022 168,681 0 298,381 - Total $ 298,756 $ 22,875 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% 1,200,000 96,000 1,104,000 250,000 166,500 93,666 February 12, 2020 42,500 one 65% 15 0 (ii) On March 15, 2021, we issued a 6% 545,000 272,500 22,500 272,500 22,500 March 11, 2022 PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I) THE GREATER CANNABIS COMPANY, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE F - NOTES PAYABLE TO THIRD PARTIES (continued) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four ( 24 70 125

DERIVATIVE LIABILITY (Tables)

DERIVATIVE LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF DERIVATIVE LIABILITY	The derivative liability consists of: SCHEDULE OF DERIVATIVE LIABILITY September 30, 2021 December 31, 2020 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ $ 17,441 Convertible Promissory Note dated March 15, 2021 and June 30, 2021 payable to FirstFire Global Opportunities Fund, LLC, See Note F (ii) - - Total derivative liability $ - $ 17,441

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Jul. 31, 2018	Mar. 10, 2017	Sep. 30, 2021
Number of shares issued		26,905,969
Advertising costs			$ 0
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation			470,599,900
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued	9,411,998
Common stock, voting rights	Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Conversion of convertible preferred stock	50
Green C Corporation [Member] | Former Share Holders [Member]
Percentage of issued and outstanding shares acquired	94.00%
Green C Corporation [Member] | Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired	100.00%
Common stock, voting rights	Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 456,358						$ 456,358		$ 112,953
Liabilities, Current	782,506						782,506
[custom:WorkingCapitalDeficit-0]	289,398						289,398
Net Income (Loss) Attributable to Parent	$ 252,278	$ 38,964	$ 114,653	$ 459,260	$ (1,102,449)	$ 1,211,569	405,895	$ 568,380
Net Cash Provided by (Used in) Operating Activities							$ 156,595	$ 260,698

NOTE RECEIVABLE (Details Narrat

NOTE RECEIVABLE (Details Narrative) - USD ($)	Jun. 10, 2020	Sep. 30, 2021	Dec. 31, 2020
Notes receivable		$ 36,750	$ 36,750
Kol Tuv Ventures, LLC [Member]
Repayment of notes receivable	$ 50,000
Interest rate	2.00%

RIGHT OF FIRST REFUSAL AGREEM_2

RIGHT OF FIRST REFUSAL AGREEMENT (Details Narrative) - Commitments [Member] - KTV [Member] - CBD [Member] - USD ($)	Jan. 30, 2020	Sep. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Paid to related party	$ 25,000
CBD opportunities term		5 years

SCHEDULE OF LOANS PAYABLE TO RE

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Total	$ 260,000	$ 260,000
Elisha Kalfa and Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Total	180,000	180,000
Fernando Bisker and Sigalush, LLC [Member]
Related Party Transaction [Line Items]
Total	$ 80,000	$ 80,000

SCHEDULE OF LOANS PAYABLE TO _2

SCHEDULE OF LOANS PAYABLE TO RELATED PARTIES (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Number of shares held by holders of preferred stock	9,111,998		9,411,998
Elisha Kalfa and Yonah Kalfa [Member]
Related Party Transaction [Line Items]
Number of shares held by holders of preferred stock		2,966,666	2,966,666
Fernando Bisker and Sigalush, LLC [Member]
Related Party Transaction [Line Items]
Number of shares held by holders of preferred stock		2,966,666	2,966,666

LOANS PAYABLE TO RELATED PART_3

LOANS PAYABLE TO RELATED PARTIES (Details Narrative) - Loan and Contribution Agreements [Member]	Jul. 31, 2018USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maturity, description	These loans were extended during the period for an additional 24 months.
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Repayments of Related Party Debt	$ 1,500,000

SCHEDULE OF NOTES PAYABLE TO TH

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) - USD ($)		Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total		$ 298,756	$ 22,875
Promissory Note [Member]
Short-term Debt [Line Items]
Total		375	375
Convertible Convertible Note One [Member]
Short-term Debt [Line Items]
Total	[1]		22,500
Convertible Promissory Notes Two [Member]
Short-term Debt [Line Items]
Total	[2]	$ 298,381
[1]	On February 12, 2019, (the “Issue Date”) the Company issued a 6% 1,200,000 96,000 1,104,000 250,000 166,500 93,666 February 12, 2020 42,500 one 65% 15 0
[2]	On March 15, 2021, we issued a 6% 545,000 272,500 22,500 272,500 22,500 March 11, 2022

SCHEDULE OF NOTES PAYABLE TO _2

SCHEDULE OF NOTES PAYABLE TO THIRD PARTIES (Details) (Parenthetical)

May 15, 2021

Mar. 15, 2021USD ($)

Jun. 03, 2020USD ($)

Feb. 12, 2020USD ($)

Jan. 17, 2020USD ($)

Feb. 13, 2019USD ($)

Feb. 12, 2019USD ($)

Mar. 28, 2017$ / shares

May 15, 2021

Jun. 30, 2021USD ($)Integer

Dec. 31, 2020USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2020USD ($)

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 325,212

$ 311,050

$ 67,082

Promissory Note [Member] | John T. Root [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

4.00%

Debt instrument, maturity date

Sep. 28, 2017

Conversion price | $ / shares

$ 0.001

Convertible Promissory Notes One [Member] | Emet Capital Partners, LLC [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Convertible Promissory Note Two [Member] | FirstFire Global Opportunities Fund, LLC [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Mar. 11, 2022

Unamortized debt discount

$ 168,681

0

Convertible Promissory Note One [Member] | Eagle Equities LLC [Member]

Short-term Debt [Line Items]

Debt instrument, principal amount

$ 1,200,000

Debt conversion, original issue discount

96,000

Funding value of issuance of note

$ 1,104,000

Convertible Promissory Note One [Member] | Eagle Equities LLC [Member] | Share-based Payment Arrangement, Tranche One [Member]

Short-term Debt [Line Items]

Proceeds from issuance of convertible debt

$ 250,000

Convertible Promissory Note One [Member] | Eagle Equities LLC [Member] | Share-based Payment Arrangement, Tranche Two [Member]

Short-term Debt [Line Items]

Proceeds from issuance of convertible debt

$ 166,500

Convertible Promissory Note One [Member] | Eagle Equities LLC [Member] | Share-based Payment Arrangement, Tranche Three [Member]

Short-term Debt [Line Items]

Proceeds from issuance of convertible debt

$ 93,666

Convertible Promissory Note One [Member] | Eagle Equities LLC [Member] | Share Based Compensation Award Tranche Four [Member]

Short-term Debt [Line Items]

Proceeds from issuance of convertible debt

$ 42,500

Convertible Convertible Note One [Member] | Eagle Equities LLC [Member]

Short-term Debt [Line Items]

Debt instrument, term

1 year

Trading days percentage

65.00%

Trading days period | Integer

15

Convertible Promissory Notes Two [Member] | FirstFire Global Opportunities Fund, LLC [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Mar. 11, 2022

Unamortized debt discount

$ 0

Debt instrument, principal amount

$ 545,000

Debt conversion, original issue discount

22,500

Proceeds from issuance of convertible debt

$ 272,500

FF Note [Member] | FirstFire Global Opportunities Fund, LLC [Member]

Short-term Debt [Line Items]

Debt instrument, interest rate

24.00%

Trading days percentage

70.00%

[custom:DebtRepaymentPercentage-0]

125.00%

FF Note [Member] | = 30 days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

105% * (Principal + Interest (“P+I”)

FF Note [Member] | 31 - 60 Days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

110% * (P+I)

FF Note [Member] | 61 - 90 Days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

115% * (P+I)

FF Note [Member] | 91 - 120 Days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

120% * (P+I)

FF Note [Member] | 121 - 150 Days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

125% * (P+I)

FF Note [Member] | 151 - 180 Days [Member]

Short-term Debt [Line Items]

Pre-payment of convertible promissory note percentage

130% * (P+I)

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITY (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total derivative liability		$ 17,441
Convertible Promissory Notes One [Member]
Short-term Debt [Line Items]
Total derivative liability		17,441
Convertible Promissory Notes Two [Member]
Short-term Debt [Line Items]
Total derivative liability

DERIVATIVE LIABILITY (Details N

DERIVATIVE LIABILITY (Details Narrative) - Convertible Promissory Notes [Member]	12 Months Ended
	Dec. 31, 2020$ / shares
Short-term Debt [Line Items]
Share Price	$ 0.003
Measurement Input, Exercise Price [Member]
Short-term Debt [Line Items]
Derivative liability measurement input	0.00169
Measurement Input, Expected Term [Member]
Short-term Debt [Line Items]
Fair value of assumption term	0 days
Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Derivative liability measurement input	1.4294
Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Derivative liability measurement input	0

CAPITAL STOCK AND WARRANTS (Det

CAPITAL STOCK AND WARRANTS (Details Narrative)	Sep. 21, 2021shares	Jul. 15, 2021USD ($)shares	Oct. 18, 2019USD ($)Integer	Feb. 14, 2019$ / sharesshares	Jul. 31, 2018shares	Mar. 10, 2017shares	Feb. 03, 2017shares	Sep. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Mar. 11, 2021$ / sharesshares	Mar. 05, 2021$ / shares
Class of Stock [Line Items]
Number of shares issued during the period, shares | shares						26,905,969
Debt instrument, principal amount | $											$ 325,212	$ 311,050	$ 67,082
Accrued interest | $								$ 18,462	$ 10,613	$ 814	$ 16,849	$ 18,462	$ 10,613	$ 11,793
Debt conversion converted shares issued | shares								115,277,834	27,563,525	13,795,118	261,215,948	115,277,834	27,563,525	21,484,688
Conversion of note payable, principal amount | $								$ 311,050	$ 67,082	$ 22,500				$ 165,350
Excess of fair value | $											$ 462,263	$ 467,554	$ 132,838	228,949
Number of stock value issued for debt conversion | $								797,067	$ 210,532	$ 45,524	804,324	797,067	210,532	406,093
Liability reduction | $											$ 342,061	$ 329,512	$ 77,695	$ 177,143
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member]
Class of Stock [Line Items]
Debt conversion converted shares issued | shares				9,000,000
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member] | First Exchange Agreement [Member]
Class of Stock [Line Items]
Debt instrument, principal amount | $			$ 20,399
Accrued interest | $			5,189
Debt instrument, periodic payment | $			$ 25,587
Debt instrument, interest rate			6.00%
Debt instrument, maturity date			Feb. 12, 2020
Trading days percentage			75.00%
Trading days period | Integer			15
Four New Convertible Warrant Notes [Member] | Emet Capital Partners, LLC [Member] | Second Exchange Agreement [Member]
Class of Stock [Line Items]
Debt instrument, periodic payment | $			$ 675,000
Debt instrument, interest rate			2.00%
Debt instrument, maturity date			Oct. 18, 2020
Trading days percentage			75.00%
Trading days period | Integer			15
FirstFire note [Member]
Class of Stock [Line Items]
Conversion price | $ / shares																$ 0.005208
Debt instrument, principal amount | $		$ 52,080
Debt conversion converted shares issued | shares		10,000,000
Fair value of warrants | $								262,429
Debt conversion, amount | $								$ 39,000
Loss on conversion of notes payable | $		$ 52,716
FirstFire Global Opportunities Fund, LLC [Member] | Warrant A [Member]
Class of Stock [Line Items]
Warrants to purchase common stock | shares															25,000,000
Warrants exercise price per share | $ / shares															$ 0.025
FirstFire Global Opportunities Fund, LLC [Member] | Warrant B [Member]
Class of Stock [Line Items]
Warrants to purchase common stock | shares															15,000,000
Warrants exercise price per share | $ / shares															$ 0.05
FirstFire Global Opportunities Fund, LLC [Member] | Warrant C [Member]
Class of Stock [Line Items]
Warrants to purchase common stock | shares															10,000,000
Warrants exercise price per share | $ / shares															$ 0.075
FirstFire Global Opportunities Fund, LLC [Member] | Warrant [Member]
Class of Stock [Line Items]
Warrants exercise price per share | $ / shares															$ 0.005
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Class of Stock [Line Items]
Number of shares issued during the period, shares | shares					9,411,998
Common stock, voting rights					Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Common stock shares issued | shares					50
Series B Convertible Preferred Stock [Member] | Emet Capital Partners, LLC [Member]
Class of Stock [Line Items]
Number of shares issued during the period, shares | shares				9,000,000
Preferred stock conversion basis, description				Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share.
Conversion price | $ / shares				$ 0.075
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Common stock shares issued | shares	15,000,000							300,000
Converted preferred stock | shares	300,000
Green C Corporation [Member] | Class A Common Stock [Member]
Class of Stock [Line Items]
Ownership percentage					100.00%
Common stock, voting rights					Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock.
Sylios Corp [Member]
Class of Stock [Line Items]
Ownership percentage						19.99%	80.01%
Number of shares issued during the period, shares | shares						5,378,476	21,527,493
Common stock, shares held | shares							500

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

May 27, 2020

Jul. 15, 2019

Jul. 31, 2018

Jun. 26, 2018

Jun. 21, 2018

Sep. 30, 2021

Sep. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Loss Contingencies [Line Items]

Forgiveness of royalty payable

$ (50,000)

$ (50,000)

Officers compensation

19,000

51,000

121,000

153,000

August 1, 2021 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

35,000

35,000

November 1, 2021 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

35,000

35,000

February 1, 2022 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

23,000

23,000

May 1, 2022 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

70,000

70,000

November 1, 2022 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

77,482

77,482

May 1, 2022 [Member]

Loss Contingencies [Line Items]

Payments on commitments purchase

$ 27,000

$ 27,000

Pharmedica Ltd [Member]

Loss Contingencies [Line Items]

Minimum annual royalty amount

$ 50,000

Impairment charge

$ 69,749

Reduction of carrying value of assets

$ 69,749

Intangible assets

$ 0

Exclusive License Agreement [Member] | Green Cs [Member]

Loss Contingencies [Line Items]

License fee

$ 100,000

Annual royalties rate

5.00%

Minimum annual royalty amount

$ 50,000

Forgiveness of royalty payable

50,000

Reduction of accrued royalties

50,000

Accrued royalties

$ 0

$ 0

Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Annual royalties rate

10.00%

Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Annual royalties rate

17.00%

Royalty payment

$ 1,000,000

Services Agreements [Member] | Chief Executive Officer [Member]

Loss Contingencies [Line Items]

Officers compensation

$ 10,000

Services Agreements [Member] | Chief Legal Officer [Member]

Loss Contingencies [Line Items]

Officers compensation

$ 7,000

Commitments [Member]

Loss Contingencies [Line Items]

Officers compensation

$ 102,000

$ 102,000